Research programme: stomatitis polyclonal antibody - Avaxia BiologicsAlternative Names: Mucositis polyclonal antibody - Avaxia Biologics
Latest Information Update: 16 Jul 2016
At a glance
- Originator Avaxia Biologics
- Class Polyclonal antibodies
- Mechanism of Action Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Stomatitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Stomatitis in USA (Topical)
- 28 Jun 2010 Avaxia Biologics receives grant from the Massachusetts Life Sciences Center for antibody development in Stomatitis
- 16 Sep 2009 Preclinical trials in Stomatitis in USA (Topical)